Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals.
Due to the increasing incidence and prevalence of neuroendocrine tumors (NETs), there is a need to assess any gaps in awareness and care. A survey was undertaken in 2017 to identify perceived unmet needs from the perspectives of patients/families, patient advocates and health care professionals (HCPs). The survey consisted of 33–37 questions (depending on type of respondent) across four areas: information, care, treatments and research.
Recent News
Rarecan Seeks Your Input on Genetic Analysis Services
Rarecan, in collaboration with its partners, is exploring the potential for offering genetic analysis services to aid in cancer treatment decisions and clinical trial eligibility. Advancements in technology have made genetic analysis of tumors increasingly...
Pancreatic Enzyme Replacement Therapy (PERT) Update – Creon®, Nutrizym® and Pancrex®.
Pancreatic Enzyme Replacement Therapy (PERT) - product brands: Creon®, Nutrizym® and Pancrex®. Many of you are aware that there has been some variability and inconsistency in the delivery and availability, at local level, of PERT. This has led to some people either...
Goblet Cell Adenocarcinoma of the Appendix (GCA)
Some of you may have seen an article published in the Mail Online (19th March) about a young mum, diagnosed with Goblet Cell Adenocarcinoma of the Appendix. Our thoughts are with this young woman and her family. However, we would like to reduce any confusion or...